Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Prior treatment

• Prior systemic anti-cancer therapy for ovarian cancer
• Prior treatment with PARP inhibitor or immune mediated therapy
• Planned intraperitoneal cytotoxic chemotherapy
• Active or prior documented autoimmune or inflammatory disorders
• History of another primary malignancy except for:
  • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study treatment and of low potential risk for recurrence (patients who have received prior adjuvant chemotherapy for early stage breast cancer may be eligible, provided that it was completed ≥3 years prior to registration, and that the patient remains free of recurrent or metastatic disease)
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated carcinoma in situ without evidence of disease
  • Endometrial cancer FIGO Stage IA, Grade 1 or Grade 2

Other illness

• Non-epithelial ovarian cancer, borderline tumors, low grade epithelial tumors or mucinous histology
• Patients considered a poor medical risk due to a serious, uncontrolled intercurrent illness
• Clinically significant cardiovascular disease
• Persistent toxicities CTCAE Grade \>2 caused by previous cancer therapy
• Patients with a known hypersensitivity to olaparib, durvalumab or any of the excipients of these products and to the combination/comparator agents

Other

• Inability to determine the presence or absence of a deleterious or suspected deleterious BRCA mutation
• Patients with known brain metastases
• Breast feeding women

• Female patients with newly diagnosed, histologically confirmed, advanced (Stage III-IV) high grade epithelial ovarian cancer including high grade serious, high grade endometriod, clear cell ovarian cancer or carcinosarcoma, primary peritoneal cancer and / or fallopian-tube cancer
• Patients must be aged ≥18 years of age. For patients enrolled in Japan that are aged \<20 year
• All patients should be candidates for cytoreductive surgery either: upfront primary surgery OR plan to undergo chemotherapy with interval debulking surgery
• Evidence of presence or absence of BRCA1/2 mutation in tumour tissue
• Mandatory provision of tumour sample for centralised tBRCA testing
• ECOG performance status 0-1
• Patients must have preserved organ and bone marrow function
• Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test